Key Insights

Highlights

Treatment Research

1 treatments under study, led by Blb01d1

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 1 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

1Total
Phase 1/2 (1)

Trial Status

Recruiting1

Clinical Trials (1)

Showing 1 of 1 trials
NCT05803018Phase 1/2RecruitingPrimary

A Study of BL-B01D1 in Patients With Multiple Solid Tumors, Including Recurrent or Metastatic Gynecological Malignancies

Showing all 1 trials

Research Network

Common Treatments

  • Blb01d11

Active Sponsors

  • Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.1
  • Sichuan Baili Pharmaceutical Co., Ltd.1

Top Investigators

Related Conditions

  • Solid Tumor1

Activity Timeline